CD205抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD205 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using CD205 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of MOLT4 cells using CD205 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of THP-1 cells using CD205 mouse mAb (green) and negative control (red).    

  
  

CD205 antibody targets the CD205 antigen, also known as DEC-205 or LY75. a type C lectin receptor primarily expressed on antigen-presenting cells (APCs) such as dendritic cells (DCs) and macrophages. Discovered in the 1980s, CD205 is a member of the macrophage mannose receptor family and plays a critical role in antigen recognition, internalization, and processing. Its structure includes multiple ligand-binding domains, such as leucine-rich repeats and a fibronectin-type II domain, enabling interactions with pathogen-associated molecular patterns (PAMPs) and endogenous glycoproteins.

CD205 facilitates antigen uptake and directs internalized antigens to MHC class II compartments, promoting efficient antigen presentation to T cells. This property has made it a key target in immunology research, particularly in vaccine development and immunotherapy. Antibodies against CD205 are widely used to study DC biology, track APCs in tissues, or deliver antigens/therapeutics to these cells. For instance, anti-CD205 conjugates enhance vaccine efficacy by selectively delivering payloads to DCs, triggering robust adaptive immune responses.

In cancer immunotherapy, CD205 antibodies are explored for targeting tumor antigens or checkpoint inhibitors to DCs. However, their role in autoimmune diseases and tolerance induction is also under investigation. Commercially available CD205 antibodies (e.g., NLDC-145. MG38.1) vary in species reactivity and applications, necessitating careful selection based on experimental needs. Ongoing research continues to unravel its regulatory mechanisms and therapeutic potential.